Results 71 to 80 of about 15,755 (201)

Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma [PDF]

, 2020
Daratumumab is a human CD38-targeted monoclonal antibody approved as monotherapy for heavily pretreated relapsed and refractory multiple myeloma. We report findings for the Spanish cohort of an open-label treatment protocol that provided early access to ...
Alegre, A, Balari, AS, Blanchard, MJ, Couturier, C, de la Rubia, J, Gaudig, M, Gonzalez, MS, Hevia, H, Insunza, A, Lleonart, JB, Mateos, MV, Milionis, I, Montero, LFC, Palomera, L, Pei, HL, Penarrubia, MJ, Potamianou, A, Rios-Tamayo, R, Rodriguez, CE, Rodriguez-Otero, P, Suarez, A   +20 more
core   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, EarlyView.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro

Brain, Behavior, & Immunity - Health
Multiple myeloma is a haematological cancer characterised by the accumulation of clonal plasma cells in the bone marrow and is commonly treated with daratumumab, an anti-CD38 monoclonal antibody immunotherapy.
Harrison D. Collier-Bain, Annabelle Emery, Frankie F. Brown, Adam J. Causer, Rebecca Oliver, Rachel Eddy, Shoji Leach, John Graby, Daniel Augustine, Sally Moore, Josephine Crowe, James Murray, James E. Turner, John P. Campbell   +13 more
doaj   +1 more source

The non-coding RNA landscape of plasma cell dyscrasias [PDF]

, 2020
Despite substantial advancements have been done in the understanding of the pathogenesis of plasma cell (PC) disorders, these malignancies remain hard-to-treat.
Azab, Kareem A, et al,, Morelli, Eugenio, Rocca, Roberta   +3 more
core   +1 more source

Monoclonal gammopathy of undetermined significance : natural course and comorbidities [PDF]

, 2017
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by an overproduction of monoclonal immunoglobulins.
Lindqvist, Ebba K
core   +1 more source

Biochemical bone biomarkers in plasma cell dyscrasias

British Journal of Haematology, EarlyView.
Visual abstract depicting that bone turnover markers reflect dynamic alterations in bone remodelling across the spectrum of plasma cell dyscrasias but remain limited by assay variability, biological confounding and incomplete integration with imaging and risk stratification.
Guido Nador, Rohit Vijjhalwar, Muhammad Kassim Javaid, Claire M. Edwards, Karthik Ramasamy   +4 more
wiley   +1 more source

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, EarlyView.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source

Interference of daratumumab with pretransfusion testing, mimicking a high-titer, low avidity like antibody

Asian Journal of Transfusion Science, 2017
Daratumumab is a monoclonal immunoglobulin against CD38 and has been approved for treating patients with refractory multiple myeloma. The presence of daratumumab in the sera can interfere with pretransfusion testing due to the weakly expression of CD38 ...
Mei-Hwa Lin, Fei-Yun Liu, Hsiu-Mien Wang, Hsin-Ching Cho, Shyh-Chyi Lo   +4 more
doaj   +1 more source

Cutaneous Crystal‐Storing Histiocytosis With Marginal Zone Lymphoma. A Case Report With A Striking Clinical Presentation

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Cutaneous crystal‐storing histiocytosis (CSH) is an extremely rare histopathologic finding of histiocytes accumulating crystals of immunoglobulin or paraproteins, often associated with lymphoplasmacytic malignancies. It commonly presents in a wide age range of both female and male adults with a history of a lymphoproliferative disorder ...
Ashton Arlen, Brad S. Graham, Gregory A. Hosler, Marsha C. Kinney   +3 more
wiley   +1 more source

P28 | ON DEMAND PLERIXAFOR FOR STEM CELL MOBILIZATION WITH G-CSF ONLY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH DARATUMUMAB: A SINGLE CENTER EXPERIENCE

Haematologica
Daratumumab is increasingly used as a part of the induction therapy in patients with newly diagnosed multiple myeloma (NDMM) and is associated with deeper responses to treatment.
B. Skopec, L. Cemazar, M. Skerget
doaj   +1 more source